Abstract
A simple and rapid high performance liquid chromatography (HPLC) method was developed and validated to determine uridine, metabolite of citicoline, in human plasma, and applied to the pharmacokinetics and bioequivalence studies of citicoline sodium tablet and capsule. Uridine and amoxicillin (used as internal standard, IS) were extracted from plasma by simple protein precipitation with perchloric acid. The separation was performed on a Phenomenex kinetex C18 (100 ×4.6 mm, 2.6μm) column, with a mobile phase of 0.05 M phosphate buffer (Potassium dihydrogen phosphate, adjusted pH to 3.5 by phosphate) - Methanol (98:2, V/V), and delivered at the flow rate of 0.8 mL/min. The calibration curve was linear over uridine concentration range of 0.05-2μg/mL (r>0.99), The main pharmacokinetic parameters of citicoline sodium tablet and capsule were as follows, t 1/2 (4.393±2.526) and (4.857±4.503) h, T max (3.354±1.118) and (3.688±1.082) h, Cmax (1.956±0.402) and (2.070±0.619) μg/mL, AUC0-12 (12.774±3.222) and (13.992±3.953) μg/mL*h, AUC0~∞ (16.015±5.647) and (17.198±6.672) μg/mL*h, respectively. The two-one side t-test analysis showed that the confidential intervals of Cmax, AUC0-12, AUC0~∞ of citicoline sodium tablet and capsule were (89.5%~102.1%), (85.3%~97.5%), (85.3%~102.9%), respectively. The relative bioavailability of citicoline sodium tablets was 92.7%. The tablet and capsule were bioequivalence.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
